Navigation Links
PTC Therapeutics to Present at European Pediatric Neurology Society Congress
Date:9/18/2013

isit our website www.ptcbio.com.

Forward Looking Statements:
Any statements in this press release about future expectations, plans and prospects for the Company, the development of and potential market for the Company's product candidates and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan" "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from those expressed or implied by these forward-looking statements. Such risks and uncertainties include, among others, those related to the initiation and conduct of clinical trials, availability of data from clinical trials, expectations for regulatory approvals, our scientific approach and general development progress, the availability or commercial potential of our product candidates and other factors discussed in the "Risk Factors" section of the final prospectus for our initial public offering, which is on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 WriteResult, LLC – a premier ... again shown superiority when it comes to meeting the ... ePRO portion of their most recent study closeout on-time ... chose WriteResult’s digital writing platform to collect Patient Reported ... to complete drew data from a number of assessments ...
(Date:8/26/2014)... , Aug. 26, 2014  NeuroSigma, Inc., a ... established to develop bioelectronic technologies, today announced that it ... the U.S. Securities and Exchange Commission relating to a ... number of shares to be offered and the price ... determined. Jefferies LLC will act as the ...
(Date:8/26/2014)... 2014 The 20 ambassadors representing the ... community issued the following statement on Facebook today regarding ... driving new funding specifically for ALS research: , “Who ... some ice would raise all this awareness and funding ... and on behalf of the entire ALS community, would ...
(Date:8/26/2014)... REHOVOT, Israel , August 26, 2014 /PRNewswire/ ... specialist, Replica 3DM, supports NHS hospitals with surgery validation using ... - Performing surgery on 3D printed models ... patient recovery and provides an effective aid for both patient ... (Nasdaq: SSYS ), a global leader of 3D ...
Breaking Biology Technology:A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 3ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 3Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 5
... DIEGO, April 9, 2008 ADVENTRX,Pharmaceuticals, Inc. (Amex: ... appointed,Jose Hechavarria to the new position of vice ... leading the company,s planned,commercial manufacturing operations., "We ... team," said Evan M.,Levine, ADVENTRX chief executive officer. ...
... future ... sales ... LOR; AMEX: LRP), a biopharmaceutical company dedicated to,the research and development ... that its subsidiary GeneSense,Technologies, Inc. ("GeneSense") has signed an exclusive multinational,license ...
... Inc. (Nasdaq: TPPH ) today announced that ... Market ("Nasdaq") formally notifying it that,Nasdaq has not ... January,2, 2008, as required by Marketplace Rule 4310(c)(14) ... will be suspended. Tapestry,does not intend to appeal ...
Cached Biology Technology:ADVENTRX Appoints Vice President of Manufacturing 2ADVENTRX Appoints Vice President of Manufacturing 3Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 2Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 3Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 4Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 5Tapestry Receives Nasdaq Delisting Notice 2
(Date:8/27/2014)... evidence puts into doubt the long-standing belief that a ... brain plays a central role in depression. In ... that mice lacking the ability to make serotonin in ... conventional wisdom) did not show depression-like symptoms. , ... VA Medical Center and Wayne State University School of ...
(Date:8/27/2014)... number of studies have shown that excessive ... of Parkinson,s disease. Previous studies from Chunyan ... in China have shown that baicalin prevented ... divalent metal transporter 1 expression, and increased ... of rotenone-induced Parkinson,s disease rats. However, the ...
(Date:8/27/2014)... Listeria is a dreaded bacterium that can be ... last few weeks, 28 persons in Denmark have been ... in supermarkets. 13 have died. , The bacterium is ... uncanny ability to adapt to changes in its surroundings, ... Together with colleagues from the Department of Biochemistry and ...
Breaking Biology News(10 mins):New study throws into question long-held belief about depression 2Researchers discover why Listeria bacterium is so hard to fight 2Researchers discover why Listeria bacterium is so hard to fight 3
... SAN DIEGO , May 11 ... Biomatrica Connect™, a solution-centric partnership program established with ... room temperature storage and management of nucleic acids. ... scientific/industry partnership for the development, testing, validation and ...
... commentary on the nature of pathogens is raising startling new ... plays in the understanding of emerging disease. Ecological speciation, and ... shifts onto a novel host, is one of the main ... argue the authors of a new paper published online in ...
... NY) A multi-institutional team of researchers, including scientists ... has received a prestigious National Institutes of Health (NIH) ... structure and function of unknown enzymes identified in genome-sequencing ... the metabolic and chemical diversity that exists in nature ...
Cached Biology News:Biomatrica Launches New Partnership Program - Biomatrica Connect(TM) 2Biomatrica Launches New Partnership Program - Biomatrica Connect(TM) 3Biomatrica Launches New Partnership Program - Biomatrica Connect(TM) 4Biomatrica Launches New Partnership Program - Biomatrica Connect(TM) 5Biomatrica Launches New Partnership Program - Biomatrica Connect(TM) 6Emergence of fungal plant diseases linked to ecological speciation 2NIH funds multicenter 'glue grant' to study enzyme function 2
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
... With the macro- and micronutrients ... Skoog (1962) and the vitamins ... al. (1968). Preparation Quantity Equivalency: ... of powder per liter of ...
Biology Products: